Adequate funding of comprehensive community-based programs for key populations needed now more than ever to reach and sustain HIV targets.

Africa HIV care continuum community differentiated care key and vulnerable populations structural interventions

Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
07 2022
Historique:
received: 17 02 2022
accepted: 06 07 2022
entrez: 26 7 2022
pubmed: 27 7 2022
medline: 29 7 2022
Statut: ppublish

Résumé

Globally, over half of the estimated new HIV infections now occur among key populations, including men who have sex with men, sex workers, people who inject drugs, transgender individuals, and people in prisons and other closed settings, and their sexual partners. Reaching epidemic control will, for many countries, increasingly require intensified programming and targeted resource allocation to meet the needs of key populations and their sexual partners. However, insufficient funding, both in terms of overall amounts and the way the funding is spent, contributes to the systematic marginalization of key populations from needed HIV services. The Joint United Nations Programme on HIV/AIDS (UNAIDS) has recently highlighted the urgent need to take action to end inequalities, including those faced by key populations, which have only been exacerbated by the COVID-19 pandemic. To address these inequalities and improve health outcomes, key population programs must expand the use of a trusted access platform, scale up differentiated service delivery models tailored to the needs of key populations, rollout structural interventions and ensure service integration. These critical program elements are often considered "extras," not necessities, and consequently costing studies of key population programs systematically underestimate the total and unitary costs of services for key populations. Findings from a recent costing study from the LINKAGES project suggest that adequate funding for these four program elements can yield benefits in program performance. Despite this and other evidence, the lack of data on the true costs of these elements and the costs of failing to provide them prevents sufficient investment in these critical elements. As nations strive to reach the 2030 UNAIDS goals, donors, governments and implementers should reconsider the true, but often hidden costs in future healthcare dollars and in lives if they fail to invest in the community-based and community-driven key population programs that address structural inequities. Supporting these efforts contributes to closing the remaining gaps in the 95-95-95 goals. The financial and opportunity cost of perpetuating inequities and missing those who must be reached in the last mile of HIV epidemic control must be considered.

Identifiants

pubmed: 35880969
doi: 10.1002/jia2.25967
pmc: PMC9318644
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25967

Informations de copyright

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Lancet. 2018 Aug 25;392(10148):698-710
pubmed: 30037733
Sex Transm Infect. 2016 Jun;92(4):292-8
pubmed: 26424712
J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):503-512
pubmed: 30649034
J Int AIDS Soc. 2021 Jun;24 Suppl 2:e25710
pubmed: 34164934
AIDS Behav. 2021 Jul;25(Suppl 1):72-83
pubmed: 31912274
Curr Opin HIV AIDS. 2014 Sep;9(5):506-13
pubmed: 25010898
Health Aff (Millwood). 2020 Sep;39(9):1647-1648
pubmed: 32897795
BMC Public Health. 2021 Sep 24;21(1):1739
pubmed: 34560878
J Int AIDS Soc. 2018 Jul;21 Suppl 5:e25126
pubmed: 30033604
AIDS Behav. 2018 Apr;22(4):1253-1264
pubmed: 29273945
BMC Infect Dis. 2021 Sep 13;21(Suppl 2):874
pubmed: 34517819
Glob Public Health. 2018 Apr;13(4):414-425
pubmed: 26979302
AIDS. 2014 Jan 28;28(3):425-34
pubmed: 24670525
J Int AIDS Soc. 2021 Jul;24 Suppl 3:e25739
pubmed: 34189863
Global Health. 2019 Dec 18;15(1):86
pubmed: 31849335
Lancet HIV. 2018 Aug;5(8):e417-e426
pubmed: 30030134
JMIR Public Health Surveill. 2020 Oct 1;6(4):e18000
pubmed: 33001039
J Int AIDS Soc. 2021 Jul;24 Suppl 3:e25718
pubmed: 34189856
PLoS One. 2014 Sep 09;9(9):e106582
pubmed: 25203052
Curr Opin HIV AIDS. 2019 Jan;14(1):60-65
pubmed: 30394947
J Int AIDS Soc. 2018 Oct;21 Suppl 7:e25167
pubmed: 30334609
J Acquir Immune Defic Syndr. 2015 Mar 1;68 Suppl 2:S74-82
pubmed: 25723994
Sex Transm Infect. 2014 Feb;90(1):19-25
pubmed: 24056777
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):605-611
pubmed: 30383587
J Int AIDS Soc. 2021 Jan;24(1):e25650
pubmed: 33533115
Sex Transm Infect. 2013 Sep;89 Suppl 2:ii11-7
pubmed: 23843454
J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):396-405
pubmed: 33234807
Nat Commun. 2020 Feb 18;11(1):773
pubmed: 32071298
Lancet HIV. 2020 May;7(5):e366-e372
pubmed: 32386723
Harm Reduct J. 2021 Feb 3;18(1):15
pubmed: 33536033
Int J STD AIDS. 2019 May;30(6):557-568
pubmed: 30727831
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
Lancet. 2015 Jan 10;385(9963):172-85
pubmed: 25059938
AIDS. 2021 Sep 1;35(11):1878-1880
pubmed: 34397488
Cult Health Sex. 2020 Sep;22(9):1001-1017
pubmed: 31429671
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25320
pubmed: 31328445
Int J Drug Policy. 2021 Apr;90:103095
pubmed: 33429163
J Int AIDS Soc. 2020 Oct;23(10):e25632
pubmed: 33119183
AIDS Behav. 2011 Aug;15(6):1088-97
pubmed: 21153432
Ann Epidemiol. 2016 Aug;26(8):557-569
pubmed: 27421700
Curr HIV/AIDS Rep. 2014 Mar;11(1):81-92
pubmed: 24384832
J Urban Health. 2006 Jan;83(1):59-72
pubmed: 16736355
Sex Transm Dis. 2019 Aug;46(8):556-562
pubmed: 31295225

Auteurs

Meghan C DiCarlo (MC)

Global Health Population and Nutrition, FHI 360, Washington, DC, USA.

Gina A Dallabetta (GA)

HIV/TB, Bill & Melinda Gates Foundation, Washington, DC, USA.

Chris Akolo (C)

Global Health Population and Nutrition, FHI 360, Washington, DC, USA.

Sergio Bautista-Arredondo (S)

Division of Health Economics and Health Systems Innovations, National Institute of Public Health (INSP), Cuernavaca, Mexico.

H Victor Digolo (HV)

Men Against AIDS Group Organization (MAAYGO), Kisumu, Kenya.

Virginia A Fonner (VA)

Global Health Population and Nutrition, FHI 360, Washington, DC, USA.

Grace Jill Kumwenda (GJ)

Pakachere Institute for Health and Development Communication, Blantyre, Malawi.

Patrick Mbulaje (P)

Centre for the Development of People, Lilongwe, Malawi.

Peninah W Mwangi (PW)

Bar Hostess Empowerment and Support Program (BHESP), Nairobi, Kenya.

Navindra E Persuad (NE)

Global Health Population and Nutrition, FHI 360, Washington, DC, USA.

Simon Sikwese (S)

Pakachere Institute for Health and Development Communication, Blantyre, Malawi.

Tisha A Wheeler (TA)

Office of HIV/AIDS, United States Agency for International Development (USAID), Washington, DC, USA.

R Cameron Wolf (RC)

Office of HIV/AIDS, United States Agency for International Development (USAID), Washington, DC, USA.

Hally R Mahler (HR)

Global Health Population and Nutrition, FHI 360, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH